United States Patent and Trademark Office Grants Patent for Vectra(R) DA
December 01 2015 - 7:05AM
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics,
Inc. (NASDAQ:MYGN), today announced that the United States Patent
and Trademark Office (PTO) has issued United States Patent No.
9,200,324. The patent, which is expected to expire in 2031,
provides intellectual property protection for Crescendo
Bioscience's Vectra® DA testing.
Vectra DA is an advanced blood test for adults with rheumatoid
arthritis (RA) and helps patients objectively track their disease
activity over time. Vectra DA measures expression levels of
twelve biomarkers that are then combined into a single
score. The twelve biomarkers measured by Vectra DA are:
VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, leptin,
resistin, SAA and CRP.
The recently issued patent is co-assigned to Crescendo and the
Oklahoma Medical Research Foundation and is the first patent issued
relating to Vectra DA. Crescendo will continue to pursue
additional patent applications, which if issued, should expand the
scope of intellectual property protection for Vectra DA.
"Crescendo's first patent for Vectra DA is significant because
it validates the innovation required to bring to market the only
objective multi-biomarker test for assessing RA disease activity,"
said Bernie Tobin, president, Crescendo Bioscience. "The PTO's
decision comes at a critical time as we enter the golden era of
personalized medicine. In order for personalized medicine to
become a reality, strong intellectual property protection is
essential because it provides research-based companies like
Crescendo with incentives to continue to invest in research and
development."
About Vectra® DA
Vectra DA is the only multi-biomarker blood test for rheumatoid
arthritis (RA) disease activity that integrates the concentrations
of 12 serum proteins associated with RA disease activity into a
single objective score, on a scale of 1 to 100, to help physicians
make more informed treatment decisions. Vectra DA testing is
performed at the Crescendo Bioscience state-of-the-art CLIA
(Clinical Laboratory Improvement Amendments) facility. Test results
are reported to the physician 5 to 7 days from shipping of the
specimen to Crescendo Bioscience. Physicians can receive test
results via standard mail, by fax or via the private web portal,
VectraView. For more information on Vectra DA, please visit:
www.Vectra-DA.com.
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad
Genetics, Inc., is a molecular diagnostics company dedicated to
developing and commercializing quantitative blood tests for
rheumatoid arthritis (RA) and other autoimmune diseases, located in
South San Francisco, Calif. Crescendo Bioscience develops
quantitative, objective, reproducible blood tests to provide
rheumatologists with deeper clinical insight to help enable more
effective management of patients with autoimmune and inflammatory
diseases. For more information, please visit the company
website at www.CrescendoBio.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad
discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose
disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where
molecular diagnostics can significantly improve patient care and
lower healthcare costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary cancer
testing markets, diversifying its product portfolio through the
introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to Patent No. 9,200,324
providing intellectual property protection for Vectra® DA testing
and the expected patent expiration date; the ability of Vectra DA
to help patients objectively track their disease activity over
time; the Company's continued pursuit of additional patent
applications; the scope of intellectual property protection of
future patents for Vectra DA; and the Company's strategic
directives under the captions "About Crescendo Bioscience" and
"About Myriad Genetics." These "forward-looking
statements" are based on management's current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by forward-looking
statements. These risks and uncertainties include, but are not
limited to: the risk that sales and profit margins of our molecular
diagnostic tests and pharmaceutical and clinical services may
decline; risks related to our ability to transition from our
existing product portfolio to our new tests, including unexpected
costs and delays; risks related to decisions or changes in
governmental or private insurers' reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; and other factors discussed under the heading
"Risk Factors" contained in Item 1A of our most recent Annual
Report on Form 10-K for the fiscal year ended June 30, 2015, which
has been filed with the Securities and Exchange Commission, as well
as any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date
of the release, and Myriad undertakes no duty to update this
information unless required by law.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024